title: CXCL10 is critical for the generation of protective CD8 T cell response induced by antigen pulsed CpG-ODN activated dendritic cells.
abstract: The visceral form of leishmaniasis is the most severe form of the disease and of particular concern due to the emerging problem of HIV/visceral leishmaniasis (VL) co-infection in the tropics. Till date miltefosine, amphotericin B and pentavalent antimony compounds remain the main treatment regimens for leishmaniasis. However, because of severe side effects, there is an urgent need for alternative improved therapies to combat this dreaded disease. In the present study, we have used the murine model of leishmaniasis to evaluate the potential role played by soluble leishmanial antigen (SLA) pulsed-CpG-ODN stimulated dendritic cells (SLA-CpG-DCs) in restricting the intracellular leishmanial growth. We found that mice vaccinated with a single dose of SLA-pulsed DC stimulated by CpG-ODN were protected against a subsequent leishmanial challenge and had a dramatic reduction in parasite burden along with the generation of parasite specific cytotoxic T lymphocytes. Moreover, we demonstrate that the induction of protective immunity conferred by SLA-CpG-DCs depends entirely on the CXC chemokine IFN-γ-inducible protein 10 (CXCL10; IP-10). CXCL10 is directly involved in the generation of a parasite specific CD8⁺ T cell-mediated immune response. We observed significant reduction of CD8⁺ T cells in mice depleted of CXCL10 suggesting a direct role of CXCL10 in the generation of CD8⁺ T cells in SLA-CpG-DCs vaccinated mice. CXCL10 also contributed towards the generation of perforin and granzyme B, two important cytolytic mediators of CD8⁺ T cells, following SLA-CpG-DCs vaccination. Together, these findings strongly demonstrate that CXCL10 is critical for rendering a protective cellular immunity during SLA-CpG-DC vaccination that confers protection against Leishmania donovani infection.
authors.affiliation: Division of Molecular Medicine, Bose Institute, P1/12, C.I.T. Scheme VII-M, Kolkata, India.
authors.forename: Saikat
authors.initials: S
authors.lastname: Majumder
authors.forename: Surajit
authors.initials: S
authors.lastname: Bhattacharjee
authors.forename: Bidisha
authors.initials: B
authors.lastname: Paul Chowdhury
authors.forename: Subrata
authors.initials: S
authors.lastname: Majumdar
mesh_terms: D000818:Animals; D000953:Antigens, Protozoan / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000378:metabolism / Q000502:physiology*; D054357:Chemokine CXCL10 / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D003713:Dendritic Cells / Q000187:drug effects / Q000276:immunology; D007111:Immunity, Cellular / Q000235:genetics / Q000502:physiology*; D056724:Immunity, Humoral; D054332:Leishmaniasis Vaccines / Q000627:therapeutic use*; D007898:Leishmaniasis, Visceral / Q000276:immunology* / Q000517:prevention & control; D051379:Mice; D008807:Mice, Inbred BALB C; D009838:Oligodeoxyribonucleotides / Q000494:pharmacology
chemical_list: D000953:Antigens, Protozoan; C408982:CPG-oligonucleotide; D054357:Chemokine CXCL10; C485433:Cxcl10 protein, mouse; D054332:Leishmaniasis Vaccines; D009838:Oligodeoxyribonucleotides